HER2 Amplification Has No Prognostic Value in Sporadic and Hereditary Ovarian Tumours

Overview

Journal Hered Cancer Clin Pract

Publisher Biomed Central

Specialty Oncology

Date 2010 Mar 13

PMID 20223002

Citations 2

Authors

Izabela Brozek

Iwona Kardas

Karolina Ochman

Jaroslaw Debniak

Maciej Stukan

Magdalena Ratajska

Lucyna Morzuch

Janusz Emerich

Janusz Limon

Affiliations

Soon will be listed here.

Abstract

Whereas HER2 amplification is a well-known phenomenon in breast tumours, its frequency and clinical importance in ovarian cancer have not been established. The aim of the study was to compare the frequency of HER2 amplification in hereditary (BRCA-positive) and sporadic (BRCA-negative) ovarian tumours and to estimate the association of this gene alteration on clinical outcome in ovarian cancer patients. We analysed HER2 amplification in 53 ovarian tumours: 20 from mutation carriers (18 in BRCA1 and 2 in BRCA2 gene) and 33 from non-carriers. Fluorescence in situ hybridization for HER2 was performed on 'touch' slides from frozen tumour samples or formalin-fixed, paraffin-embedded tissue. Our results indicate that high amplification (HER2: centromere ratio>5) is an infrequent phenomenon in ovarian tumours (6/53 cases). It occurs in both hereditary (4/20) and sporadic (2/33) tumours and no difference in the frequency of HER2 amplification exists between these groups. There is no significant difference in the clinical outcome of patients with HER2 amplified and non-amplified tumours (p = 0.3). Our results suggest a different biological role of HER2 amplification in ovarian and breast cancer.

Citing Articles

The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies.

Luo H, Xu X, Ye M, Sheng B, Zhu X PLoS One. 2018; 13(1):e0191972.

PMID: 29381731 PMC: 5790275. DOI: 10.1371/journal.pone.0191972.

Prognostic value of HER-2/neu expression in epithelial ovarian cancer: a systematic review and meta-analysis.

Wang K, Guan C, Yu J, Jin X, Sun L, Zheng L Oncotarget. 2017; 8(43):75528-75543.

PMID: 29088888 PMC: 5650443. DOI: 10.18632/oncotarget.20657.

References

Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R . Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 1990; 50(13):4087-91. View

Santin A, Bellone S, Van Stedum S, Bushen W, De Las Casas L, Korourian S . Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecol Oncol. 2005; 98(1):24-30. DOI: 10.1016/j.ygyno.2005.03.041. View

Rubin S, Finstad C, Wong G, Almadrones L, Plante M, LLOYD K . Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis. Am J Obstet Gynecol. 1993; 168(1 Pt 1):162-9. DOI: 10.1016/s0002-9378(12)90907-2. View

Hengstler J, Lange J, Kett A, Dornhofer N, MEINERT R, Arand M . Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer. Cancer Res. 1999; 59(13):3206-14. View

Schorge J, Muto M, Lee S, Huang L, Welch W, Bell D . BRCA1-related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis. Cancer Res. 2000; 60(5):1361-4. View

Grushko T, Blackwood M, Schumm P, Hagos F, Adeyanju M, Feldman M . Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res. 2002; 62(5):1481-8. View

Bookman M, Darcy K, Clarke-Pearson D, Boothby R, Horowitz I . Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol. 2003; 21(2):283-90. DOI: 10.1200/JCO.2003.10.104. View

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron J, Nobel A . Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100(14):8418-23. PMC: 166244. DOI: 10.1073/pnas.0932692100. View

Camilleri-Broet S, Hardy-Bessard A, Le Tourneau A, Paraiso D, Levrel O, Leduc B . HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Ann Oncol. 2003; 15(1):104-12. DOI: 10.1093/annonc/mdh021. View

10.

Chan J, Loizzi V, Magistris A, Lin F, Rutgers J, Osann K . Differences in prognostic molecular markers between women over and under 45 years of age with advanced ovarian cancer. Clin Cancer Res. 2004; 10(24):8538-43. DOI: 10.1158/1078-0432.CCR-04-0626. View

11.

Verri E, Guglielmini P, Puntoni M, Perdelli L, Papadia A, Lorenzi P . HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study. Oncology. 2005; 68(2-3):154-61. DOI: 10.1159/000086958. View

12.

Tanner B, Kreutz E, Weikel W, MEINERT R, Oesch F, Knapstein P . Prognostic significance of c-erB-2 mRNA in ovarian carcinoma. Gynecol Oncol. 1996; 62(2):268-77. DOI: 10.1006/gyno.1996.0226. View

13.

Rhei E, Bogomolniy F, Federici M, Maresco D, Offit K, Robson M . Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers. Cancer Res. 1998; 58(15):3193-6. View

14.

Jacobs T, Gown A, Yaziji H, Barnes M, Schnitt S . Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol. 1999; 17(7):1974-82. DOI: 10.1200/JCO.1999.17.7.1974. View

15.

Hogdall E, Christensen L, Kjaer S, Blaakaer J, Bock J, Glud E . Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer. 2003; 98(1):66-73. DOI: 10.1002/cncr.11476. View

16.

Espinosa A, Tabernero M, Garcia-Macias M, Primo D, Gomez Bernal A, Cruz J . Her-2/neu gene amplification in familial vs sporadic breast cancer. Impact on the behavior of the disease. Am J Clin Pathol. 2003; 120(6):917-27. DOI: 10.1309/5H77-8W5K-75CM-M03W. View

17.

Lassus H, Leminen A, Vayrynen A, Cheng G, Gustafsson J, Isola J . ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol Oncol. 2004; 92(1):31-9. DOI: 10.1016/j.ygyno.2003.10.010. View

18.

Lakhani S, Manek S, Penault-Llorca F, Flanagan A, Arnout L, Merrett S . Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res. 2004; 10(7):2473-81. DOI: 10.1158/1078-0432.ccr-1029-3. View

19.

Adem C, Soderberg C, Hafner K, Reynolds C, Slezak J, Sinclair C . ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers. Genes Chromosomes Cancer. 2004; 41(1):1-11. DOI: 10.1002/gcc.20057. View

20.

Tanabe H, Nishii H, Sakata A, Suzuki K, Mori Y, Shinozaki H . Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma. Gynecol Oncol. 2004; 94(3):735-9. DOI: 10.1016/j.ygyno.2004.05.055. View